ST-1891

Phase 2Small molecule

SSention Therapeutics, LLC

ST-1891 is one of 19 small molecule programs targeting Hypothyroidism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypothyroidismActive, not recruiting

HypothyroidismPhase 2

Active, not recruiting

Competition

Competitive Landscape

43 competitors in Hypothyroidism

#DrugCompanyPhaseTrials

Synthroid

IInstitut Jerome Lejeune

Approved

22 2

Tricor

JJagotec

Approved

—3

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Growth Hormone

1 5

Triiodothyronine

HHadassah Medical Organization

Approved

1 6

L-Carnitine

IIperboreal Pharma Srl

Approved

1 7

Calcitonin

TTarsa Therapeutics, Inc.

Approved

1 8

Levothyroxin

BBerlin-Chemie AG Menarini Group

Approved

4 9

L-Thyroxine

SShandong Provincial Hospital

Approved

3 10

Farxiga

AstraZeneca

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypothyroidism1 trial

A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism

Completed·SSention Therapeutics, LLC·Phase 2·NCT05412979·490 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ST-1891. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ST-1891 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ST-1891. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sention Therapeutics, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSention Therapeutics, LLC

ST-1891

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypothyroidism1 trial

References

Drug Info

Quick Facts

Related News